This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Insmed (INSM) Starts Dosing in Phase III Bronchiectasis Study
by Zacks Equity Research
Insmed (INSM) doses the first patient in the phase III ASPEN study evaluating its pipeline candidate brensocatib for the treatment of patients with bronchiectasis.
Acceleron (XLRN) Gets Orphan Drug Tag for ACE-1334 by FDA
by Zacks Equity Research
The FDA grants orphan drug designation to Acceleron's (XLRN) ACE-1334 for the treatment of patients with systemic sclerosis.
Amicus (FOLD) Initiates Rolling BLA Submission for AT-GAA
by Zacks Equity Research
Amicus (FOLD) initiates a rolling biologics license application (BLA) submission to the FDA for AT-GAA, for the treatment of late onset Pompe disease.
Blueprint Medicines' (BPMC) Gavreto Approved for Thyroid Cancer
by Zacks Equity Research
The FDA grants accelerated nod to Blueprint Medicines' (BPMC) Gavreto for treating patients with advanced/metastatic RET-altered thyroid cancer.
Strength Seen in Aptose (APTO): Stock Soars 5.3%
by Zacks Equity Research
Aptose (APTO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Autolus Therapeutics (AUTL) Surges: Stock Moves 9.2% Higher
by Zacks Equity Research
Autolus Therapeutics (AUTL) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Aptose (APTO) Initiates Phase I a/b Study in Leukemia Patients
by Zacks Equity Research
Aptose (APTO) doses first patient with acute myeloid leukemia in a phase I a/b study with CG-806, with a starting dose of 450 mg.
Aptose Biosciences (APTO) Surges: Stock Moves 9.8% Higher
by Zacks Equity Research
Aptose Biosciences (APTO) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
New Strong Sell Stocks for August 28th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
Are You Looking for a Top Momentum Pick? Why Aptose Biosciences (APTO) is a Great Choice
by Zacks Equity Research
Does Aptose Biosciences (APTO) have what it takes to be a top stock pick for momentum investors? Let's find out.
Factors to Know Ahead of Talos Energy's (TALO) Q4 Earnings
by Zacks Equity Research
Talos Energy's (TALO) fourth-quarter earnings are expected to have taken a hit from lower realized commodity prices.
Daqo New Energy (DQ) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
Our proven model does not conclusively predict an earnings beat for Daqo New Energy (DQ) this season.
Are Options Traders Betting on a Big Move in Aptose (APTO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
Top Ranked Momentum Stocks to Buy for January 29th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, January 29th
Is the Options Market Predicting a Spike in Aptose (APTO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aptose (APTO) stock based on the movements in the options market lately.
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Middlesex Water, Howard Hughes, Ubiquiti, Aptose and Aytu
Bond Yields Plunge Globally on Slowdown Fears: 5 Safe Picks
by Nalak Das
A growing number of central banks are giving signals for pursuing easy monetary policy in order to raise inflation and generate economic growth.
Will Difficult Comparison Hurt Bio-Rad's (BIO) Q4 Earnings?
by Zacks Equity Research
Bio-Rad (BIO) apprehends a year-over-year decline in revenues within Life Sciences segment due to difficult comparison.
Will Hospice Strength Show on Amedisys' (AMED) Q4 Earnings?
by Zacks Equity Research
An increased reimbursement of approximately $1 million has boosted Amedisys' (AMED) Hospice business.
Aptose Biosciences Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Aptose Biosciences has been struggling lately, but the selling pressure may be coming to an end soon.
New Strong Sell Stocks for July 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
New Strong Sell Stocks for July 23rd
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Aptose Biosciences (APTO) Could Be Positioned for a Slump
by Zacks Equity Research
Aptose Biosciences (APTO) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions as well.
New Strong Sell Stocks for July 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
Although Arena's (ARNA) only approved product, Belviq, has an unimpressive show so far, the company's efforts to improve the drug's performance might drive the stock in Q4.